Alexia Iasonos

Associate Attending Biostatistician

Pictured: Alexia Iasonos

Office Phone



Current Research Interests

Dr. Alexia Iasonos’ expertise is in the design and analysis of clinical trials, primarily dose finding Phase I trials that are model based, as well as predictive modeling in surgical outcomes. Her methodological research is focused on evaluating Bayesian adaptive Phase I designs, specifically the Continual Reassessment Method (CRM). She has compared CRM with the standard 3+3 dose escalation scheme [Abstract] as part of a 2-year award from the Experimental Therapeutic Center of Memorial Sloan Kettering to study dose finding algorithms. She has lead a team of programmers and data managers to create the infrastructure (software and a web interface) that facilitates clinical personnel in obtaining the dose allocation for CRM seamlessly. Her clinical collaborations focus on gynecologic malignancies. Her work with gynecologic oncologists and surgeons varies from exploring biomarkers to predicting survival outcomes. Most recently she has evaluated clinical endpoints for consolidation or maintenance trials given to patients in remission.

Alexia has previously worked with QoL outcomes as part of collaboration with Health Outcomes (HOGR) where the group analyzed patient reported outcomes and compared these with clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events. She has also worked with the Urology group in developing predictive models and nomograms that can be used pre-operatively to enable a more informed clinical decision-making process. She has been a statistical reviewer for the institutional Data and Safety Monitoring Committee for Phase I-II trials since 2006.

She is currently the primary statistician for the Gynecology service, Developmental Therapeutic Center and Quality Control Initiative at Memorial Sloan Kettering. She is serving as a scientific reviewer on the institution’s Research Council and the ASCO Grants selection committee.


University of Albany


Iasonos A, Sabbatini P, Spriggs DR, Aghajanian CA, O’Cearbhaill RE, Hensley ML, Thaler HT. Identifying Clinical Improvement in Consolidation Single-arm Phase II Trials in Ovarian Cancer Patients in Second or Greater Clinical. International Journal of Gynecological Cancer 2011 Nov 11. [Epub ahead of print]. [PubMed Abstract]

Iasonos A, Zohar S, O’Quigley J. Incorporating lower grade toxicity information into dose finding designs. Clin Trials. 2011;8(4):370-9. [PubMed Abstract]

Iasonos A., Ostrovnaya I. Estimating the dose-toxicity curve in completed phase I studies. Statistics in Medicine 2011 Jul 30;30(17):2117-29. [PubMed Abstract]

Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials. 2008;5(5):465-77. [PubMed Abstract]

Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008 Mar 10;26(8):1364-70. Review. [PubMed Abstract]

Read more

  1. Raj GV, Iasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer. J Clin Oncol. 2006 Jul 1;24(19):3095-100. [PubMed Abstract]

  2. Abu-Rustum NR, Alektiar K, Iasonos A, Lev G, Sonoda Y, Aghajanian C, Chi DS, Barakat RR. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan Kettering Cancer Center. Gynecol Oncol. 2006 Nov;103(2):714-8. Epub 2006 Jun 5.  [PubMed Abstract]

  3. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K. Phase I Study of the Anti-Idiotype Monoclonal Antibody Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Clin Cancer Res 2006; 12:5503-10.

  4. Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol. 2007 Jan;104(1):176-80. Epub 2006 Sep 25. [PubMed Abstract]

  5. Raj GV, Bach AM, Iasonos A, Korets R, Blitstein J, Hann L, Russo P. Predicting the histology of renal masses using preoperative Doppler ultrasonography. J Urol. 2007 Jan;177(1):53-8. [PubMed Abstract]

  6. Diefenbach CS, Soslow RA, Iasonos A, Linkov I, Hedvat C, Bonham L, Singer J, Barakat RR, Aghajanian C, Dupont J. Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival. Cancer. 2006 Oct 1;107(7):1511-9. [PubMed Abstract]

  7. Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W, Spriggs D, Fleisher M, Thaler H, Dupont J. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007 Feb;104(2):435-42. Epub 2006 Oct 4. [PubMed Abstract]

  8. Sabbatini P, Mooney D, Iasonos A, Thaler H, Aghajanian C, Hensley M, Konner J, Spriggs D, Abu-Rustum NR, Dupont J. Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy. Int J Gynecol Cancer. 2007 May-Jun;17(3):589-94. Epub 2007 Feb 9. [PubMed Abstract]

  9. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006 Nov;7(11):903-9. [PubMed Abstract]

  10. Galsky MD, Iasonos A, Mironov S, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer. 2007 Feb 1;109(3):549-55. [PubMed Abstract]

  11. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs. 2007 Jun;25(3):265-270. Epub 2006 Dec 5. [PubMed Abstract]

  12. Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher HI, McCabe M, Schrag D. Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc. 2007 May-Jun;14(3):264-8. Epub 2007 Feb 28. [PubMed Abstract]

  13. Dos Santos L, Mok E, Iasonos A, Park K, Soslow RA, Aghajanian C, Alektiar K, Barakat RR, Abu-Rustum NR. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol. 2007 May;105(2):321-4. Epub 2007 Jan 22. [PubMed Abstract]

  14. Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansihefsky SJ, Livingston PO. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res. 2007 Jul 15;13(14):4170-7. [PubMed Abstract]

  15. Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, Herr HW, Russo P, Boyle MG, Bajorin DF. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007 Feb;69(2):255-9. [PubMed Abstract]

  16. Harrison ML, Gore ME, Spriggs D, Kaye S, Iasonos A, Hensley M, Aghajanian C, Venkatraman E, Sabbatini P. Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials. Gynecol Oncol. 2007 Sep;106(3):469-75. Epub 2007 Jul 5. [PubMed Abstract]

  17. Black D, Iasonos A, Ahmed H, Chi DS, Barakat RR, Abu-Rustum NR. Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer. Gynecol Oncol. 2007 Jul 3; [Epub ahead of print] [PubMed Abstract]

  18. Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Iasonos A, Sabbatini P. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer. 2007 Dec 1;110(11):2448-56. [PubMed Abstract]

  19. Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schrag D. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol. 2007 Dec 1;25(34):5374-80. [PubMed Abstract]

  20. Juretzka M, Hensley ML, Tew W, Konner J, Aghajanian C, Leitao M, Iasonos A, Soslow R, Park K, Sabbatini P. A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. Eur J Gynaecol Oncol. 2008;29(6):568-72.

  21. Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials. 2008;5(5):465-77.  [PubMed Abstract]

  22. Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2008 Feb;108(2):287-92. Epub 2007 Nov 13. [PubMed Abstract]

  23. Caceres A, Zhou Q, Iasonos A, Gerdes H, Chi DS, Barakat RR. Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series. Gynecol Oncol. 2008 Mar;108(3):482-5. Epub 2008 Jan 10. [PubMed Abstract]

  24. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008 Mar 10;26(8):1364-70. Review. [PubMed Abstract]

  25. Black D, Levine DA, Nicoll L, Chou JF, Iasonos A, Brown CL, Sonoda Y, Chi DS, Leitao MM, Abu-Rustum NR, Ferguson SE, Barakat RR. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol. 2008 Apr;109(1):39-42. Epub 2008 Jan 29. [PubMed Abstract]

  26. Abu-Rustum NR, Iasonos A, Zhou Q, Oke E, Soslow RA, Alektiar KM, Chi DS, Barakat RR. Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? Am J Obstet Gynecol. 2008 Apr;198(4):457.e1-5; discussion 457.e5-6. [PubMed Abstract]

  27. Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, Iasonos A, Lee H, Dupont B, Pezzulli S, Jungbluth AA, Old LJ, Dupont J. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res. 2008 May 1;14(9):2740-8. [PubMed Abstract]

  28. Thompson RH, Ordonez MA, Iasonos A, Secin FP, Guillonneau B, Russo P, Touijer K. Renal cell carcinoma in young and old patients—is there a difference? J Urol. 2008 Oct;180(4):1262-6; discussion 1266. Epub 2008 Aug 15. [PubMed Abstract]

  29. Makker V, Abu-Rustum NR, Alektiar KM, Aghajanian CA, Zhou Q, Iasonos A, Hensley ML. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecol Oncol. 2008 Nov;111(2):249-54. Epub 2008 Aug 27.

  30. Zivanovic O, Alektiar KM, Sonoda Y, Zhou Q, Iasonos A, Tew WP, Diaz JP, Chi DS, Barakat RR, Abu-Rustum NR. Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy. Gynecol Oncol. 2008 Nov;111(2):265-70. Epub 2008 Sep 6.

  31. Zivanovic O, Leitao MM, Iasonos A, Jacks LM, Zhou Q, Abu-Rustum NR, Soslow RA, Juretzka MM, Chi DS, Barakat RR, Brennan MF, Hensley ML. Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol. 2009 Apr 20;27(12):2066-72. Epub 2009 Mar 2.

  32. Milowsky MI, Nanus DM, Maluf FC, Mironov S, Shi W, Iasonos A, Riches J, Regazzi A, Bajorin DF. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol. 2009 Sep 1;27(25):4062-7. Epub 2009 Jul 27.

  33. Zivanovic O, Sima CS, Iasonos A, Bell-McGuinn KM, Sabbatini PJ, Leitao MM, Levine DA, Gardner GJ, Barakat RR, Chi DS. Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol. 2009 Nov;115(2):209-14. Epub 2009 Aug 7. [PubMed Abstract]

  34. Gallagher DJ, Milowsky MI, Iasonos A, Maluf FC, Russo P, Dalbagni G, Donat MS, Boyle MG, Zheng J, Riches J, Bajorin DF. Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. Cancer. 2009 Nov 15;115(22):5193-201.

  35. O’Cearbhaill R, Zhou Q, Iasonos A, Soslow RA, Leitao MM, Aghajanian C, Hensley ML. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol. 2009 Nov 23. [Epub ahead of print]

  36. O’Cearbhaill R, Zhou Q, Iasonos A, Hensley ML, Tew WP, Aghajanian C, Spriggs DR, Lichtman SM, Sabbatini PJ. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol. 2009 Nov 25. [Epub ahead of print]

  37. Garg K, Shih K, Barakat R, Zhou Q, Iasonos A, Soslow RA. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol. 2009 Dec;33(12):1869-77.

  38. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D. Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes. J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32. Epub 2009 Nov 17. [PubMed Abstract]

  39. Sabbatini P, Spriggs D, Aghajanian C, Hensley M, Tew W, Konner J, Bell-McGuinn K, Juretzka M, Iasonos A. Consolidation strategies in ovarian cancer: observations for future clinical trials. Gynecol Oncol. 2010 Jan;116(1):66-71.

  40. Abu-Rustum NR, Zhou Q, Gomez JD, Alektiar KM, Hensley ML, Soslow RA, Levine DA, Chi DS, Barakat RR, Iasonos A. A Nomogram for Predicting Overall Survival of Women with Endometrial Cancer Following Primary Therapy: Toward Improving Individualized Cancer Care Gynecol Oncol. 2010 Mar;116(3):399-403.

  41. Carter J, Sonoda Y, Baser RE, Raviv L, Chi DS, Barakat RR, Iasonos A, Brown CL, Abu-Rustum NR. A 2-year prospective study assessing the emotional, sexual,and quality of life concerns of women undergoing radical trachelectomy versusradical hysterectomy for treatment of early-stage cervical cancer. Gynecol Oncol. 2010 Nov;119(2):358-65. [PubMed Abstract]

  42. Shih KK, Zhou QC, Aghajanian C, Huh J, Soslow RA, Morgan JC, Iasonos A, Chi DS, Barakat RR, Abu-Rustum NR. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Gynecol Oncol. 2010 Nov;119(2):270-3. Epub 2010 Aug 16. [PubMed Abstract]

  43. Fu M, Maresh EL, Soslow RA, Alavi M, Mah V, Zhou Q, Iasonos A, Goodglick L, Gordon LK, Braun J, Wadehra M. Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer. Clin Cancer Res. 2010 Aug 1;16(15):3954-63. [PubMed Abstract]

  44. Dharma Rao T, Park KJ, Smith-Jones P, Iasonos A, Linkov I, Soslow RA, Spriggs DR. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16. Appl Immunohistochem Mol Morphol. 2010 Oct;18(5):462-72. [PubMed Abstract]

  45. Moskowitz CH, Schöder H, Teruya-Feldstein J, Sima C, Iasonos A, Portlock CS, Straus D, Noy A, Palomba ML, O’Connor OA, Horwitz S, Weaver SA, Meikle JL, Filippa DA, Caravelli JF, Hamlin PA, Zelenetz AD. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large  B-Cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1896-903. Epub 2010 Mar 8. [PubMed Abstract]

  46. Carter J, Raviv L, Appollo K, Baser RE, Iasonos A, Barakat RR. A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors. Gynecol Oncol. 2010 May;117(2):317-23. Epub 2010 Feb 16. [PubMed Abstract]

  47. Zivanovic O, Sima CS, Iasonos A, Hoskins WJ, Pingle PR, Leitao MM Jr, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS. The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. Gynecol Oncol. 2010 Mar;116(3):351-7. [PubMed Abstract]

  48. Shih KK, Zhou Q, Huh J, Morgan JC, Iasonos A, Aghajanian C, Chi DS, Barakat RR, Abu-Rustum NR. Risk factors for recurrence of ovarian borderline tumors. Gynecol Oncol. 2010 Dec 9. [Epub ahead of print] [PubMed Abstract]

  49. Iasonos A., Ostrovnaya I. Estimating the dose-toxicity curve in completed phase I studies. Statistics in Medicine 2011 Jul 30;30(17):2117-29.

  50. Gerecitano J, Portlock C, Hamlin P, Moskowitz CH, Noy A, Straus D, Schulman P, Dumitrescu O, Sarasohn D, Pappanicholaou J, Iasonos A, Zhang Z, Mo Q, Horanlli E, Rojas CN, Zelenetz AD, O’Connor OA. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clin Cancer Res. 2011 Apr 15;17(8):2493-501. Epub 2011 Feb 23.

  51. Abu-Rustum NR, Zhou Q, Iasonos A, Alektiar KM, Leitao MM Jr, Chi DS, Sonoda Y, Soslow R, Hensley M, Barakat RR. The revised 2009 FIGO staging system for endometrial cancer: should the 1988 FIGO stages IA and IB be altered? Int J Gynecol Cancer. 2011 Apr;21(3):511-6

  52. Zivanovic O, Jacks LM, Iasonos A, Leitao MM Jr, Soslow RA, Veras E, Chi DS, Abu-Rustum NR, Barakat RR, Brennan MF, Hensley ML. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer. 2011 Jul 12. doi: 10.1002/cncr.26333.

  53. Iasonos A, Zohar S, O’Quigley J. Incorporating lower grade toxicity information into dose finding designs. Clin Trials. 2011;8(4):370-9.

  54. Hyman DM, Zhou Q, Arnold AG, Grisham RN, Iasonos A, Kauff ND, Spriggs D. Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol. 2011;123(2):196-9.

  55. Hensley ML, Kravetz S, Jia X, Iasonos A, Tew W, Pereira L, Sabbatini P, Whalen C, Aghajanian CA, Zarwan C, Berlin S. Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: A 2-cohort, phase 2 study. Cancer 2012;118(9):2403-10.

  56. Iasonos A, Sabbatini P, Spriggs DR, Aghajanian CA, O’Cearbhaill RE, Hensley ML, Thaler HT. Identifying clinical improvement in consolidation single-arm phase II trials in patients with ovarian cancer in second or greater clinical remission. Int J Gynecol Cancer 2012;22(1):63-9.

  57. Konner JA, Grabon DM, Gerst SR, Iasonos A, Thaler H, Pezzulli SD, Sabbatini PJ, Bell-McGuinn KM, Tew WP, Hensley ML, Spriggs DR, Aghajanian CA. A Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal Stage II/III epithelial ovarian cancer. J Clin Oncol. 2011;29(35):4662-8.

  58. Hyman D, Zhou Q, Iasonos A, Grisham R, Arnold AG, Phillips MF, Bhatia J, Levine D, Aghajanian C, Barakta RR, Spriggs DR, Kauff ND. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 2012;118(15):3703-9.

  59. Polterauer S, Zhou Q, Grimm C, Seebacher V, Reinthaller A, Hofstetter G, Concin N, Leitao MM, Barakat RR, Abu-Rustum NR, Iasonos A. External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. Gyn Oncology 2012;125(3):526-30.

  60. Tanner EJ, Long KC, Zhou Q, Brightwell RM, Gardner GJ, Abu-Rustum NR, Leitao MM Jr, Sonoda Y, Barakat RR, Iasonos A, Chi DS. Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer. Gynecol Oncol. 2012;125(3):526-30.

  61. Grisham RN, Adaniel C, Hyman DM, Ma W, Iasonos A, Aghajanian C, Konner J. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience. Int J Gynecol Cancer. 2012;22(5):807-11.

  62. Iasonos A., O’Quigley J. Interplay of priors and skeletons in two-stage continual reassessment method. Statistics in Medicine 2012;31(30):4321-36.

  63. Iasonos A, Mrinal Gounder  M, Spriggs DR, Gerecitano JF, Hyman DM,  Zohar S, O’Quigley J. The impact of non–drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. Clinical Cancer Research 2012;18(19):5179-87.

  64. Grisham RN, Iyer G, Garg K, Delair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, Levine DA, Aghajanian C, Solit DB. BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2013;119(3):548-54.

  65. Balar AV, Apolo A, Ostrovnaya I, Mironov S, Iasonos A, Trout A, Regazzi AM, Garcia-Grossman IR, Gallagher DJ, Milowsky MI, Bajorin DF. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol. 2013; 31(6):724-30.


  1. Iasonos A. Statistics for the beginners in gynaecologic oncology. Textbook of Gynaecological Oncology,  ESGO-ENYGO Endorsed. Gunes Tıp Kıtabevleri, 2009, p. 150.

  2. Iasonos A., O’Quigley J. Continual reassessment and related designs in dose finding studies. Statistics in Medicine. 2011 Jul 30;30(17):2057-61. Editorial.

  3. O’Quigley J, Iasonos A. Dose finding designs based on the continual reassessment method.  Handbook of Statistics in Clinical Oncology ed. by John Crowley and Маrcеl Dеkkеr. 2011.

My Events

My Pages